Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,135 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Upper Limb Clear all
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 9:44 AM EDT
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 3, 2026, 9:44 AM EDT
Not yet recruiting Not applicable Interventional

Effect of a Microprocessor-controlled Prosthetic Knee Joint on K2 Level Ambulators

NCT07103798
View directory record Official record
Conditions
Transfemoral Amputation, Limb Loss, Limb Absence
Interventions
College Park ICON, Conventional NMPK
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Estradiol Levels in Patients Treated With Estring

NCT01923298
View directory record Official record
Conditions
Estrogen Levels Among Breast Cancer Patients
Interventions
Estradiol
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 3, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

NCT02132598
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 3, 2026, 9:44 AM EDT
Active, not recruiting Phase 1 Interventional

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

NCT04577326
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM)
Interventions
cyclophosphamide, CAR T cells
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Terminated Not applicable Interventional Results available

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

NCT04779489
View directory record Official record
Conditions
Bladder Cancer
Interventions
personalized ultrafractionated stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT02096055
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Guadecitabine, Idarubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
70 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 3, 2026, 9:44 AM EDT
Not yet recruiting No phase listed Observational

Clinical Outcomes After Treatment of Distal Humerus Fractures With the LORRAINE 2.5/3.5 mm Distal Humerus System

NCT07774091
View directory record Official record
Conditions
Intra-Articular or Extra-Articular Distal Humerus Fracture, Distal Humerus Fracture
Interventions
LORRAINE 2.5/3.5 mm Distal Humerus System
Device
Lead sponsor
Bonebridge AG
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

NCT03616184
View directory record Official record
Conditions
Graft-versus-host-disease (GVHD)
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Tampa, Florida • Omaha, Nebraska • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 3, 2026, 9:44 AM EDT
Active, not recruiting Not applicable Interventional

The BD Liverty™ TIPS Stent Graft Study

NCT05711316
View directory record Official record
Conditions
Portal Hypertension, TIPS
Interventions
BD Liverty™ TIPS Stent Graft
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

NCT01686958
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-Guided Transurethral US Ablation of Prostate Tissue
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 3, 2026, 9:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

NCT07751640
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions
Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
Biological
Lead sponsor
Apeiron Research Center
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty

NCT01225250
View directory record Official record
Conditions
Rhinoplasty
Interventions
Polydioxanone (PDS) plates, Caudal septal extension graft performed through endonasal rhinoplasty
Device · Procedure
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Mind-Body Training for Hand Rehabilitation

NCT02459847
View directory record Official record
Conditions
Arm Injuries, Hand Injuries
Interventions
Mindfulness Training, Sonographic Biofeedback, Standard Care
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

NCT03580655
View directory record Official record
Conditions
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
Interventions
Avapritinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Stanford, California • Chicago, Illinois • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
86
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

NCT01754389
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Tacrolimus, Methotrexate, Bortezomib, Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke

NCT05854485
View directory record Official record
Conditions
Stroke
Interventions
REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group, Robot only group
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 3, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 3, 2026, 9:44 AM EDT
Not listed Phase 1 Interventional

Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation

NCT00388752
View directory record Official record
Conditions
Phantom Limb, Residual Limb Pain, Traumatic Amputation, Amputation
Interventions
Acupuncture
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Sep 3, 2026, 9:44 AM EDT
Recruiting Phase 4 Interventional

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026
View directory record Official record
Conditions
Psoriatic Arthritis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
53
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501, US-licensed Humira®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
63
States / cities
Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 3, 2026, 9:44 AM EDT